Results 201 to 210 of about 4,027,257 (319)

Digital Microfluidics in Newborn Screening for Mucopolysaccharidoses: A Progress Report. [PDF]

Int J Neonatal Screen, 2020
Washburn J, Millington DS.
europepmc   +1 more source

Final progress report (+ other interim progress reports)

Final progress report (+ other interim progress reports). The interim progress reports will be delivered at regular 6-monthly intervals.
openaire   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Ethiopian paediatric oncology registry progress report: documentation practice improvements at tertiary care centre in Addis Ababa, Ethiopia. [PDF]

Arch Dis Child, 2021
Levy S, Fentie AM, Buhlinger K, Clark SM, Korones DN, Miller V, Alexander TB, Weitzman S, Bekele W, Broas J, Shad A, Roberts M, Chargualaf M, Fufa D, Hailu T, Yimer MA, Mustefa M, Said Gidey AM, Dinkiye AM, Adam H, Hailu D, Muluneh B.   +21 more
europepmc   +1 more source

Reporting Progress

American Journal of Public Health and the Nations Health, 1936
openaire   +3 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Correction to: The "State of Implementation" Progress Report (SIPREP): a pilot demonstration of a navigation system for implementation. [PDF]

Implement Sci Commun, 2020
Miech EJ, Larkin A, Lowery JC, Butler AJ, Pettey KM, Rattray NA, Penney LS, Myers J, Damush TM.   +8 more
europepmc   +1 more source

Geisinger's effort to realize its potential as a learning health system: A progress report. [PDF]

Learn Health Syst, 2021
Davis FD, Williams MS, Stametz RA.
europepmc   +1 more source

A Progress Report on Prostate Cancer [PDF]

, 1990
Eugene R. Todd
openalex   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source